A. Mathioudakis (Stockport, United Kingdom), A. Spanevello (Milano, Italy)
Digital spacer informed inhaler adherence education: the OUTERSPACE proof-of-concept study in COPD
B. Dierick (Groningen, Netherlands), S. Been Buck (Groningen, Netherlands), T. Klemmeier (Groningen, Netherlands), P. Hagedoorn (Groningen, Netherlands), S. Van De Hei (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), J. Kocks (Groningen, Netherlands), T. Zijp (Groningen, Netherlands), D. Touw (Groningen, Netherlands), J. Van Boven (Groningen, Netherlands)
|   |
Mortality outcomes associated with oral corticosteroid use in patients with COPD
G. Tse (Singapore, Singapore), D. Price (Singapore, Singapore), M. Bafadhel (Oxford, United Kingdom), A. Papi (Ferrara, Italy), V. Carter (Singapore, Singapore), C. Ariti (Singapore, Singapore), J. Zhou (Singapore, Singapore), D. Skinner (Singapore, Singapore), X. Xu (Gaithersburg, MD, United States), H. Müllerová (Cambridge, United Kingdom), B. Emmanuel (Gaithersburg, MD, United States)
| |
Ventilation and tissue oxygenation patterns induced by LABA and LAMA in COPD patients
S. Perez Bogerd (Brussels, Belgium), A. Van Muylem (Brussels, Belgium), E. Maufroy (Brussels, Belgium), Y. El.Khloufi (Brussels, Belgium), S. Zengin (Brussels, Belgium), V. Faoro (Brussels, Belgium), A. Malinovschi (Uppsala, Sweden), A. Michils (Brussels, Belgium)
| |
Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD
S. Muiser (Groningen, Netherlands), K. Imkamp (Groningen, Netherlands), D. Seigers (Groningen, Netherlands), N. Halbersma (Groningen, Netherlands), J. Vonk (Groningen, Netherlands), B. Luijk (Utrecht, Netherlands), G. Braunstahl (Rotterdam, Netherlands), J. Van Den Berg (Zwolle, Netherlands), B. Kroesen (Groningen, Netherlands), J. Kocks (Groningen, Netherlands), I. Heijink (Groningen, Netherlands), H. Reddel (Sydney, Australia), H. Kerstjens (Groningen, Netherlands), M. Van Den Berge (Groningen, Netherlands)
| |
Effect of benralizumab on recurrent COPD exacerbations
D. Singh (Manchester, United Kingdom), G. Criner (Philadelphia, United States), A. Agusti (Barcelona, Spain), M. Bafadhel (Oxford, United Kingdom), J. Söderström (Gothenburg, Sweden), G. Luporini Saraiva (Gaithersburg, United States), Y. Song (Gaithersburg, United States), I. Licaj (Cambridge, United States), M. Jison (Gaithersburg, United States), U. Martin (Gaithersburg, United States), I. Psallidas (Cambridge, United Kingdom)
| |
Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease
H. Park (Seoul, Republic of Korea), S. Lim (Seoul, Republic of Korea), S. Shin (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), T. Shin (Chuncheon, Republic of Korea), K. Jung (Anyang, Republic of Korea), K. Yoo (Seoul, Republic of Korea), K. Hwang (Iksan, Republic of Korea), Y. Jo (Seoul, Republic of Korea)
| |
Inhaled corticosteroids and the risk of new-onset arterial hypertension in patients with chronic obstructive pulmonary disease
H. Meteran (Hvidovre, Denmark), P. Sivapalan (Hellerup, Denmark), J. Eklöf (Hellerup, Denmark), M. Saeed (Hellerup, Denmark), A. Jordan (Hellerup, Denmark), J. Jensen (Hellerup, Denmark)
| |
Sufficient inspiratory effort for a Dry Powder Inhaler - do we have to measure it, or can we observe it? Post hoc analysis of the PIFotal study
M. Leving (Groningen, Netherlands), S. Bosnic-Anticevich (Sydney, Australia), J. Van Cooten (Groningen, Netherlands), J. Correia De Sousa (Braga, Portugal), B. Cvetkovski (Sydney, Australia), R. Dekhuijzen (Nijmegen, Netherlands), L. Dijk (Groningen, Netherlands), M. Garcia Pardo (Palma de Mallorca, Spain), A. Gardev (Ingelheim am Rhein, Germany), R. Gawlik (Katowice, Poland), I. Van Der Ham (Groningen, Netherlands), Y. Jansen (Groningen, Netherlands), F. Lavorini (Florence, Italy), T. Maricoto (Covilha, Portugal), J. Meijer (Groningen, Netherlands), B. Metz (Groningen, Netherlands), D. Price (Aberdeen, United Kingdom), M. Roman Rodriguez (Palma de Mallorca, Spain), K. Schuttel (Groningen, Netherlands), N. Stoker (Groningen, Netherlands), I. Tsiligianni (Rethymno, Greece), O. Usmani (London, United Kingdom), J. Kocks (Groningen, Netherlands)
| |
Risk for exacerbation, hospitalization and mortality in Global Initiative for Chronic Obstructive Lung Disease group B patients with and without exacerbations: a cohort study
L. Vanfleteren (Gothenburg, Sweden), L. Holmstrand (Gothenburg, Sweden), A. Lindberg (Umeå, Sweden), C. Zhou (Gothenburg, Sweden), F. Nyberg (Gothenburg, Sweden), C. Stridsman (Gothenburg, Sweden)
| |
Recombinant AAT-Fc fusion protein INBRX-101 achieves normal serum AAT levels in patients with alpha-1 antitrypsin deficiency (AATD)
A. Veale (Auckland, New Zealand), H. Farah (Hannibal, United States), R. Mahadeva (Cambridge, United Kingdom), M. Baker (Auckland, New Zealand), B. Kuhn (Sacramento, United States), A. Cole (Christchurch, New Zealand), C. Chang (Hamilton, New Zealand), C. Brown (Indianapolis, United States), M. Campos (Miami, United States), J. Kalabus (La Jolla, United States), T. Boyea (La Jolla, United States), C. Veldstra (La Jolla, United States), V. Andrianov (La Jolla, United States), S. Bhagwat (La Jolla, United States), B. Eckelman (La Jolla, United States), J. Loscano (Gainesville, United States), M. Brantly (Gainesville, United States)
| |
Efficacy and safety of ICS/LABA/LAMA FDCs in COPD: a network meta-analysis
P. Rogliani (Roma (RM), Italy), M. Cazzola (Roma (RM), Italy), S. Verri (Roma (RM), Italy), F. Camardelli (Roma (RM), Italy), L. Calzetta (Parma, Italy), L. Calzetta (Roma (RM), Italy)
| |
Blood, nasal and airway immune responses to SARS-COV-2 vaccination in COPD patients and healthy subjects
T. Southworth (Manchester (Greater Manchester), United Kingdom), N. Jackson (Manchester (Greater Manchester), United Kingdom), D. Singh (Manchester (Greater Manchester), United Kingdom)
| |
TriOptimize IX: Real-world improvement in COPD symptoms and lung function by extrafine single-inhaler triple therapy (efSITT)
F. Trinkmann (Heidelberg, Germany), S. Bahari Javan (Hamburg, Germany), C. Criée (Bovenden, Germany), V. Bogoevska (Hamburg, Germany), C. Gessner (Leipzig, Germany)
| |
Adherence to umeclidinium/vilanterol versus inhaled corticosteroids/long-acting ß2-agonist in patients with chronic obstructive pulmonary disease in England
A. Czira (Brentford, Middlesex, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), C. Castillo (Bollington, Cheshire, United Kingdom), J. Yeap (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), M. Duarte (Brentford, Middlesex, United Kingdom), K. Rothnie (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States)
| |
SHORT-TERM OXYGEN THERAPY OUTCOMES IN COPD
T. Soumagne (Paris, France), F. Maltais (Québec, Canada), F. Corbeil (Trois RivièresQuébec, Canada), B. Paradis (Laval, Canada), M. Balzan (Montreal, Canada), P. Simao (Matosinhos, Portugal), A. Abad Fernandez (Getafe, Spain), R. Lecours (Lévi, Canada), S. Bernard (Québec, Canada), Y. Lacasse (Québec, Canada)
| |
COPD clinical course in patient with Gln27Glu polymorphism of ADRB2 gene
K. Dmytriiev (21029, Ukraine), Y. Mostovoy (21029, Ukraine), N. Slepchenko (21029, Ukraine), Y. Smereka (21029, Ukraine), D. Dmytriiev (21029, Ukraine), K. Dmytriiev (Vinnitsya, Ukraine)
| |
How does Arg16Gly polymorphism affect pulmonary function and treatment response in COPD patients?
N. Slepchenko (Vinnytsya, Ukraine), Y. Mostovoy (Vinnytsya, Ukraine), K. Dmytriiev (Vinnytsya, Ukraine), Y. Smereka (Vinnytsya, Ukraine), D. Dmytriiev (Vinnytsya, Ukraine)
| |
EVELUT: dyspnoea and symptom burden in COPD patients switching from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
R. Buhl (Mainz, Germany), M. Dreher (Aachen, Germany), M. Mattiucci-Guehlke (Ingelheim, Germany), S. Eckhardt (Gießen, Germany), C. Taube (Essen, Germany), C. Vogelmeier (Marburg, Germany), R. Buhl (Mainz, Germany)
| |
Relationship between severity of airflow obstruction and GOLD classification in COPD patients
N. Karamarkovic Lazarušic (Zagreb, Croatia), B. Butorac Petanjek (Zagreb, Croatia), L. Basara (Zagreb, Croatia), M. Jeric (Varaždin, Croatia), G. Pavliša (Zagreb, Croatia)
| |
Late Breaking Abstract - Evaluating multiple eosinophil measurements when stepping up to ICS/LAMA/LABA triple therapy in patients with COPD: a post-hoc analysis of ETHOS
D. Singh (Manchester, United Kingdom), M. Bafadhel (London, United Kingdom), J. Hurst (London, United Kingdom), P. Darken (Gaithersburg, MD, United States), M. Patel (Cambridge, United Kingdom)
| |